362 related articles for article (PubMed ID: 20457695)
1. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
[TBL] [Abstract][Full Text] [Related]
2. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
[TBL] [Abstract][Full Text] [Related]
3. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.
Mabry R; Snavely M
IDrugs; 2010 Aug; 13(8):543-9. PubMed ID: 20721825
[TBL] [Abstract][Full Text] [Related]
6. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules.
Jordan JL; Arndt JW; Hanf K; Li G; Hall J; Demarest S; Huang F; Wu X; Miller B; Glaser S; Fernandez EJ; Wang D; Lugovskoy A
Proteins; 2009 Dec; 77(4):832-41. PubMed ID: 19626705
[TBL] [Abstract][Full Text] [Related]
7. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
10. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
11. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
Fennell BJ; McDonnell B; Tam AS; Chang L; Steven J; Broadbent ID; Gao H; Kieras E; Alley J; Luxenberg D; Edmonds J; Fitz LJ; Miao W; Whitters MJ; Medley QG; Guo YJ; Darmanin-Sheehan A; Autin B; Shúilleabháin DN; Cummins E; King A; Krebs MR; Grace C; Hickling TP; Boisvert A; Zhong X; McKenna M; Francis C; Olland S; Bloom L; Paulsen J; Somers W; Jensen A; Lin L; Finlay WJ; Cunningham O
MAbs; 2013; 5(6):882-95. PubMed ID: 23995618
[TBL] [Abstract][Full Text] [Related]
12. Antibody therapeutics, antibody engineering, and the merits of protein stability.
Demarest SJ; Glaser SM
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
[TBL] [Abstract][Full Text] [Related]
13. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody.
Igawa T; Tsunoda H; Kikuchi Y; Yoshida M; Tanaka M; Koga A; Sekimori Y; Orita T; Aso Y; Hattori K; Tsuchiya M
Protein Eng Des Sel; 2010 Aug; 23(8):667-77. PubMed ID: 20576629
[TBL] [Abstract][Full Text] [Related]
14. Construction of multiform scFv antibodies using linker peptide.
Wang S; Zheng C; Liu Y; Zheng H; Wang Z
J Genet Genomics; 2008 May; 35(5):313-6. PubMed ID: 18499076
[TBL] [Abstract][Full Text] [Related]
15. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
Lu D; Zhu Z
Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
[TBL] [Abstract][Full Text] [Related]
16. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
17. A modular IgG-scFv bispecific antibody topology.
Orcutt KD; Ackerman ME; Cieslewicz M; Quiroz E; Slusarczyk AL; Frangioni JV; Wittrup KD
Protein Eng Des Sel; 2010 Apr; 23(4):221-8. PubMed ID: 20019028
[TBL] [Abstract][Full Text] [Related]
18. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
19. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
Albrecht H; Denardo GL; Denardo SJ
J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
[TBL] [Abstract][Full Text] [Related]
20. Rapid optimization and prototyping for therapeutic antibody-like molecules.
Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
